1-3 of 3
Irene A. Eiseman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

George R. Simon, Christopher R. Garrett, Stephen C. Olson, Michael Langevin, Irene A. Eiseman, John J. Mahany, Charles C. Williams, Richard Lush, Adil Daud, Pamela Munster, Alberto Chiappori, Mayer Fishman, Gerold Bepler, Peter F. Lenehan, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4645–4651.
https://doi.org/10.1158/1078-0432.CCR-05-2379
Published: 09 August 2006
View article titled, Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study
Open the PDF for Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study in another window
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

Linda L. Garland, Manuel Hidalgo, David S. Mendelson, David P. Ryan, Banu K. Arun, Jennifer L. Lovalvo, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Joseph P. Eder
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4274–4282.
https://doi.org/10.1158/1078-0432.CCR-05-2507
Published: 20 July 2006
View article titled, A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors in another window
Journal Articles

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study

Emiliano Calvo, Anthony W. Tolcher, Lisa A. Hammond, Amita Patnaik, Johan S. de Bono, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Heather McCreery, Patricia LoRusso, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7112–7120.
https://doi.org/10.1158/1078-0432.CCR-04-1187
Published: 08 November 2004
View article titled, Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: <subtitle>A Phase I Pharmacokinetic and Food Effect Study</subtitle>
Open the PDF for Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: <subtitle>A Phase I Pharmacokinetic and Food Effect Study</subtitle> in another window